To further investigate CD169 as a contributing factor in SARS-CoV-2 infection and COVID-19 disease, CD169 RMFI was evaluated in COVID-19 patients hospitalized in the Policlinic of Tor Vergata in Rome and correlated with their inflammatory and im-munological statuses, as well as respiratory outcomes. The gene discussed is SIGLEC1; the disease is COVID-19.